Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

(NASDAQ: MYGN), a leader in genetic testing and precision medicine ... These efforts, combined with prudent management of our ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

The catalogue of genetic factors that have been implicated in kidney disease continues to grow. In this guide to gene–disease relationships, the authors discuss the crucial process whereby ...

Adam Brufsky, MD, PhD, professor of medicine at the University of Pittsburgh School of Medicine; Megan Kruse, MD, breast medical oncologist at Cleveland Clinic; and Ruta Rao, MD, professor of medicine ...

If you’ve had genetic testing, you might choose to share the results with your family members. If a family member has had genetic testing, you may be interested in knowing their results. When you ...

Myriad Genetics (MYGN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

The younger the age when cancer develops, the more likely the disease is to be related to a particular genetic defect ... with microsatellite instability testing. a HNPCC-associated cancers ...